Modi Yasha S, Goduni Lediana, Moini Hadi, Gibson Andrea, Boucher Nick, Lucas Genevieve, Dhoot Dilsher S
New York University Langone Health, New York, NY, USA.
Regeneron Pharmaceuticals Inc, Tarrytown, NY, USA.
J Vitreoretin Dis. 2021 Mar 1;5(6):505-512. doi: 10.1177/2474126421989225. eCollection 2021 Nov-Dec.
We evaluated the relationship between dosing frequency of intravitreal antivascular endothelial growth factor (anti-VEGF) agents and visual acuity (VA) outcomes over 2 years in eyes with macular edema (ME) secondary to central retinal vein occlusion (CRVO) in the US routine clinical practice setting.
This retrospective analysis assessed electronic medical records of eyes with ME secondary to CRVO that received their first anti-VEGF injection January 1, 2012, to May 31, 2016, and were followed for 1 year or more in the US-based Vestrum Health Treatment and Outcomes database. Eyes were divided into 2 injection frequency subcohorts (≤6 or ≥7 injections/year).
Overall, 851 (34.6%) of 2458 eyes with ME secondary to CRVO received 6 or fewer injections, and 1607 (65.4%) received 7 or more injections through 1 year. The mean number of injections in patients receiving 6 or fewer injections and 7 or more injections was 4.7 and 8.8, respectively, and baseline mean VA was 35 and 37 letters, respectively. At year 1, mean letter gain from baseline was less in eyes receiving 6 or fewer injections vs in those receiving 7 or more injections (7.0 vs 12.2, < .001). Mean VA at year 2 was 50 letters in eyes receiving 6 or fewer injections (n = 50) and 55 letters in eyes receiving 7 or more injections (n = 157).
In routine clinical practice, more frequent dosing with anti-VEGF agents was associated with greater visual benefits in eyes with ME secondary to CRVO.
在美国常规临床实践环境中，我们评估了玻璃体内抗血管内皮生长因子（anti-VEGF）药物给药频率与视网膜中央静脉阻塞（CRVO）继发黄斑水肿（ME）患者2年以上视力（VA）结果之间的关系。
这项回顾性分析评估了2012年1月1日至2016年5月31日首次接受抗VEGF注射、在美国Vestrum Health治疗与结果数据库中随访1年或更长时间的CRVO继发ME患者的电子病历。将患者分为2个注射频率亚组（每年≤6次或≥7次注射）。
总体而言，2458例CRVO继发ME患者中，851例（34.6%）接受了6次或更少的注射，1607例（65.4%）在1年内接受了7次或更多的注射。接受6次或更少注射和7次或更多注射的患者平均注射次数分别为4.7次和8.8次，基线平均视力分别为35和37个字母。在第1年，接受6次或更少注射的患者与接受7次或更多注射的患者相比，从基线开始的平均字母增益较少（7.0对12.2，<0.001）。接受6次或更少注射的患者（n = 50）在第2年的平均视力为50个字母，接受7次或更多注射的患者（n = 157）为55个字母。
在常规临床实践中，CRVO继发ME患者更频繁地使用抗VEGF药物给药与更好的视力获益相关。
